Anti-myelin-associated glycoprotein neuropathy

Current Opinion in Neurology

Volumn 19, Issue 5, 2006, Pages 458-463

  Steck, Andreas J ^a   Stalder, Anna K ^a   Renaud, Susanne ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Demyelinating neuropathy; Myelin associated glycoprotein; Rituximab; Skin biopsy

Indexed keywords

CLADRIBINE; FLUDARABINE; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; MYELIN ASSOCIATED GLYCOPROTEIN ANTIBODY; PROTEIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; B LYMPHOCYTE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CLINICAL TRIAL; DEMYELINATING NEUROPATHY; DEMYELINATION; ELECTRODIAGNOSIS; ELECTROPHYSIOLOGY; GENETIC ANALYSIS; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; NERVE BIOPSY; NERVE CONDUCTION; NERVE FIBER DEGENERATION; NONHUMAN; POLYNEUROPATHY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SCHWANN CELL; SIGNAL TRANSDUCTION; SKIN BIOPSY;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN M; MYELIN-ASSOCIATED GLYCOPROTEIN; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 33748679473     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000245368.36576.0d     Document Type: Review

References (43)

1. Braun PE, Frail DE, Latov N. Myelin-associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem 1982; 39:1261-1265.
2. Steck AJ, Murray N, Meier C, et al. Demyelinating neuropathy and monoclonal IgM antibody to myelin-associated glycoprotein. Neurology 1983; 33:19-23.
3. Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 2006; 66:742-744.
4. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74:485-489.
5. Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987; 62:719-731.
6. Nobile-Orazio E, Barbieri S, Baldini L, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand 1992; 85:383-390.
7. Caudie C, Vial C, Petiot P, et al. Monoclonal IgM autoantibody activity vis-a-vis glycoconjugates of peripheral nerves: apropos of 112 cases. Ann Biol Clin (Paris) 2001; 59:567-577.
8. Katz JS, Saperstein DS, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology 2000; 54:615-620.
9. Radziwill AJ, Steck AJ, Renaud S, Fuhr P. Distal motor latency and residual latency as sensitive markers of anti-MAG polyneuropathy. J Neurol 2003; 250:962-966.
10. Capasso M, Torrieri F, Di Muzio A, et al. Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy? Clin Neurophysiol 2002; 113:346-353.
11. Attarian S, Azulay JP, Boucraut J, et al. Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies. Clin Neurophysiol 2001; 112:457-463.
12. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glyco protein and sulphated glucuronyl paragloboside. Brain 1994; 117 (Pt 5):941-947.
13. Renaud S, Steck AJ, Latov N. Neuropathies associated with monoclonal gammopathy. In: Antel J, Birnbaum G, Hartung HP, Vincent A, editors. Clinical neuroimmunology, 2nd ed Oxford: Oxford University Press; 2005. pp. 327-337.
14. Isoardo G, Deaglio S, Cocito D, et al. Immunodetection of anti-MAG IgM antibody by cross-reactivity to LA-N-1 neuroblastoma cells. J Neuroimmunol 2005; 161:78-86.
15. Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology 1996; 47:1042-1048.
16. Holland NR, Crawford TO, Hauer P, et al. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases. Ann Neurol 1998; 44:47-59.
17. Rosenberg N. The diagnostic value of skin biopsies in patients with possible small fibre neuropathy: a systematic review. Lancet Neurol (in press).
18. Lombardi R, Erne B, Lauria G, et al. IgM deposits on skin nerves in antimyelin-associated glycoprotein neuropathy. Ann Neurol 2005; 57:180-187. The authors demonstrate nicely the presence of IgM deposition myelinated nerve fibers in simple punch skin biopsies in patients with anti-MAG polyneuropathy.
19. Li J, Bai Y, Ghandour K, et al. Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain 2005; 128:1168-1177. A demonstration that skin biopsies can be used to study demyelinating neuropathies. In this study the authors used morphological and molecular techniques.
20. Gabriel JM, Erne B, Pareyson D, et al. Gene dosage effects in hereditary peripheral neuropathy: expression of peripheral myelin protein 22 in Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies nerve biopsies. Neurology 1997; 49:1635-1640.
21. McArthur JC, Griffin JW. Another tool for the neurologist's toolbox. Ann Neurol 2005; 57:163-167.
22. Erb M, Flueck B, Kern F, et al. Unraveling the differential expression of the two isoforms of myelin-associated glycoprotein in a mouse expressing GFP-tagged S-MAG specifically regulated and targeted into the different myelin compartments. Mol Cell Neurosci 2006; 17:249-253.
23. Crocker PR, Varki A. Siglecs, sialic acids and innate immunity. Trends Immunol 2001; 22:337-342.
24. Schachner M, Bartsch U. Multiple functions of the myelin-associated glycoprotein MAG (siglec-4a) in formation and maintenance of myelin. Glia 2000; 29:154-165.
25. Kursula P, Lehto VP, Heape AM. The small myelin-associated glycoprotein binds to tubulin and microtubules. Brain Res Mol Brain Res 2001; 87:22-30.
26. Trapp BD, Andrews SB, Wong A, et al. Co-localization of the myelin-associated glycoprotein and the microfilament components, F-actin and spectrin, in Schwann cells of myelinated nerve fibres. J Neurocytol 1989; 18:47-60.
27. Franzen R, Tanner SL, Dashiell SM, et al. Microtubule-associated protein 1B: a neuronal binding partner for myelin-associated glycoprotein. J Cell Biol 2001; 155:893-898.
28. Lauren J, Airaksinen MS, Saarma M, Timmusk T. Two novel mammalian Nogo receptor homologs differentially expressed in the central and peripheral nervous systems. Mol Cell Neurosci 2003; 24:581-594.
29. Yamashita T, Higuchi H, Tohyama M. The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho. J Cell Biol 2002; 157:565-570.
30. Tang S, Shen YJ, DeBellard ME, et al. Myelin-associated glycoprotein interacts with neurons via a sialic acid binding site at ARG118 and a distinct neurite inhibition site. J Cell Biol 1997; 138:1355-1366.
31. Pan B, Fromholt SE, Hess EJ, et al. Myelin-associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: neuropathology and behavioral deficits in single- and double-null mice. Exp Neurol 2005; 195:208-217.
32. Dashiell SM, Tanner SL, Pant HC, Quarles RH. Myelin-associated glycoprotein modulates expression and phosphorylation of neuronal cytoskeletal elements and their associated kinases. J Neurochem 2002; 81:1263-1272.
33. Cai Z, Cash K, Swift J, Blumbergs PC, et al. Focal myelin swellings and tomacula in anti-MAG IgM paraproteinaemic neuropathy: novel teased nerve fiber studies. J Peripher Nerv Syst 2001; 6:95-101.
34. Fruttiger M, Montag D, Schachner M, Martini R. Crucial role for the myelin-associated glycoprotein in the maintenance of axon-myelin integrity. Eur J Neurosci 1995; 7:511-515.
35. Yin X, Crawford TO, Griffin JW, et al. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci 1998; 18:1953-1962.
36. Lunn MP, Crawford TO, Hughes RA, et al. Antimyelin-associated glycoprotein antibodies alter neurofilament spacing. Brain 2002; 125:904-911.
37. Wilson HC, Lunn MP, Schey S, Hughes RA. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry 1999; 66:575-580.
38. Ghosh A, Littlewood T, Donaghy M. Cladribine in the treatment of IgM paraproteinemic polyneuropathy. Neurology 2002; 59:1290-1291.
39. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999; 52:1701-1704.
40. Rojas-Garcia R, Gallardo E, de Andres I, et al. Chronic neuropathy with IgM antiganglioside antibodies: lack of long term response to rituximab. Neurology 2003; 61:1814-1816.
41. Broglio L, Lauria G. Worsening after rituximab treatment in antimag neuropathy. Muscle Nerve 2005; 32:378-379.
42. Noronha V, Fynan TM, Duffy T. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia. J Clin Oncol 2006; 24:e3.
43. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003; 27:611-615.